HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19 Drives 11% Price Rise For Cough and Cold OTCs In UK

Executive Summary

Online price of cough and cold OTCs up double-digits in past week, according to the UK's Office for National Statistics. Paracetamol and vitamin D among other popular health products to record price rises.

You may also be interested in...



Paracetamol Prices Continue To Rise In UK

Online prices of paracetamol in the UK increased by more than 2% in the past week in the wake of the COVID-19 outbreak, according to the Office for National Statistics. By contrast, prices for cough and cold drugs fell after a double-digit rise the previous week.

Supplementation During COVID-19? An Industry Perspective

Feature: Should consumers be turning to food supplements to support their immune systems during the COVID-19 epidemic? HBW Insight speaks to Professor David Richardson, scientific adviser to the Council for Responsible Nutrition UK and Nick Bennett, head of Nutrition at IVC Brunel Healthcare Ltd.  

COVID-19 Prompts OTC Sales Restrictions Across Europe

Countries across Europe are restricting sales of OTC drugs in response to COVID-19 to maintain supply and counteract stockpiling. The approach varies widely across the region: countries such as Germany and France have introduced strict limits, while others, such as the UK and Ireland, have not ordered official restrictions. HBW Insight presents an analysis of the actions taken by 14 European countries to the upsurge in demand for OTCs.

Related Content

Topics

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel